Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022.

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that Company's Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day, to be held in-person in New York, NY from November 14-15, 2022.

Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Carsten Brunn - President and Chief Executive Officer Kevin Tan - Chief Financial Officer Peter Traber - Chief Medical Officer Takashi Kishimoto - Chief Scientific Officer Conference Call Participants Elizabeth Scott - SVB Securities Rick Miller - Cantor Fitzgerald Yun Zhong - BTIG John Newman - Canaccord Tiffany Marchell - William Blair Boobalan Pachaiyappan - H.C. Wainwright Uy Ear - Mizuho Operator Good morning, and welcome to the Selecta Biosciences Third Quarter 2022 Financial Results and Business Update Conference Call.

Selecta Biosciences, Inc. (SELB) Q3 2022 Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 –

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update

Data to be featured in one poster and two oral presentations Data to be featured in one poster and two oral presentations

Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells. The leukocyte integrins were found to be part of a larger family of integrins involved in fundamental cell interactions related to embryonic development, hemostasis and other processes and discovered by Lasker Award co-winners Dr. Richard Hynes and Dr. Erkki Rouslahti. Selecta's Chief Scientific Officer, Kei Kishimoto, Ph.D., was a key contributor to this foundational work during his time in Dr. Springer's lab.

Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions

Tritium DCFC Ltd

MicroVision

Windtree Therapeutics

Westport Fuel Systems

Hot penny stocks to watch & what happened in the stock market today. The post What The Stock Market Did Today & Top Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What The Stock Market Did Today & Top Penny Stocks To Watch Now

WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company's Management will participate in upcoming investor conferences in September.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company's Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022.

Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of ImmTOR and PDC-E2 co-administration.

Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Kevin Tan – Chief Financial Officer Carsten Brunn – President and Chief Executive Officer Peter Traber – Chief Medical Officer Kei Kishimoto – Chief Scientific Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Yun Zhong – BTIG Yatin Suneja – Guggenheim Partners John Newman – Canaccord Raju Prasad – William Blair Boobalan Pachaiyappan – H.C. Wainwright Operator Good day, and welcome to the Selecta Bio Second Quarter 2022 Earnings Release Conference Call.

Selecta Biosciences, Inc's (SELB) CEO Carsten Brunn on Q2 2022 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 –

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Selecta Biosciences, Inc. (SELB) Upgraded to Strong Buy: Here's What You Should Know

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company's Management will participate virtually in a fireside chat and in one-on-one investor meetings at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference, to be held virtually and in-person in New York, NY July 12-13.

Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies-

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

SVB Leerink initiated Selecta Biosciences Inc (NASDAQ: SELB) coverage with an Outperform rating and a price target of $7. The analysts view ImmTOR's approach to mitigate ADAs as de-risked by early clinical data from SEL-212 and believe that the ability to tame the immune.

SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company's Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.

Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q1 2021 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Carsten Brunn - President & Chief Executive Officer Kevin Tan - Chief Financial Officer Peter Traber - Chief Medical Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants John Newman - Canaccord Kristen Kluska - Cantor Fitzgerald Yun Zhong - BTIG Raju Prasad - William Blair Uy Ear - Mizuho Boobalan Pachaiyappan - HC Wainwright Chang Liu - Needham Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

Selecta Biosciences (SELB) CEO Carsten Brunn on Q1 2022 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 80.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates

– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 –

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Data to be featured in two oral presentations and four poster presentations Data to be featured in two oral presentations and four poster presentations

News for Selecta Biosciences Stock (SELB)